Research peptide

DSIP

DSIP appears in online sleep and recovery discussions. This page tracks the topic as a source-backed index entry pending deeper evidence review.

Regulatory watch Last reviewed 2026-06-30 Next review 2026-07-24

Evidence snapshot

Avoid sleep-treatment framing unless the exact claim is backed by reviewed primary sources.

Scheduled for FDA advisory committee discussion in July 2026.

Online discussion can blur anecdote, media commentary, and evidence.

Needs source expansion before any broader explainer is published.

Evidence level: Primary regulatory

Sources: U.S. Food and Drug Administration

Keep copy regulatory and source-led until the review is refreshed.

Source records are stored in the repo and linked from each claim.

U.S. Food and Drug Administration · Primary regulatory · 2026-07-23 · accessed 2026-06-30

FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.

U.S. Food and Drug Administration · Primary regulatory · 2026-01-01 · accessed 2026-06-30

FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.